Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07605052 · ClinicalTrials.gov registry record · Phase 1
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT07605052 is a Phase 1 study that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 50 participants.
The verdict
NCT07605052, a Phase 1 study, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.
Interventions
- DRUG Cagrilintide B
- DRUG Cagrilintide D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-05-20 |
| Est. Completion | 2026-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07605052
The ClinicalTrials.gov registry entry for NCT07605052 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cagrilintide B is the first listed.
NCT07605052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07605052 about?
NCT07605052 is a clinical study titled "A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight". The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be ...
What is the current status of trial NCT07605052?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-05-20. Estimated completion is 2026-09-03.
What interventions are being tested in trial NCT07605052?
The interventions under investigation include: Cagrilintide B (DRUG), Cagrilintide D (DRUG).
Who is sponsoring clinical trial NCT07605052?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.